Harmony Biosciences Holdings (HRMY) — Cash Flow Quality Index
Harmony Biosciences Holdings (HRMY) has a Cash Flow Quality Index of 1.23x as of June 2026. Operating cash flow of $92.43 Million exceeds net income of $75.43 Million, indicating high earnings quality where cash backs reported profits. Explore HRMY operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Harmony Biosciences Holdings Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for Harmony Biosciences Holdings across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of Harmony Biosciences Holdings.
Annual Cash Flow Quality Index for Harmony Biosciences Holdings (2021–2025)
Year-by-year earnings quality comparison for Harmony Biosciences Holdings.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.19x | $348.20 Million | $158.69 Million | ▲ +45.2% |
| 2024 | 1.51x | $219.82 Million | $145.49 Million | ▼ -11.3% |
| 2023 | 1.70x | $219.39 Million | $128.85 Million | ▲ +113.9% |
| 2022 | 0.80x | $144.47 Million | $181.47 Million | ▼ -72.1% |
| 2021 | 2.85x | $98.56 Million | $34.60 Million | — |